financetom
Business
financetom
/
Business
/
WeWork plans to file for bankruptcy: WSJ report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WeWork plans to file for bankruptcy: WSJ report
Nov 1, 2023 2:09 AM

WeWork Inc. plans to file for bankruptcy as early as next week, the Wall Street Journal reported Tuesday.

Share Market Live

NSE

The company had one of the most dramatic trajectories of the last startup boom — reaching a valuation of $47 billion before a disastrous attempt at an initial public offering and challenges to its co-working model during the pandemic.

In a filing Tuesday, the company said it has been holding discussions with creditors about “improving its balance sheet” and taking steps to “rationalise its real estate footprint.” On Monday, the company entered into a forbearance agreement with its creditors that will end in seven days.

A spokesperson for the company said it would “not comment on speculation,” and pointed to the filing, saying the forbearance agreement will give the company “time to continue in the positive conversations with our key financial stakeholders and engage with them to implement our ongoing strategic efforts to enhance our capital structure.” The company has “a clear, long-term vision for the future,” the spokesperson said.

The New York-based co-working company debuted in 2010, just as the market for venture capital was beginning a decade-long boom. With co-founder Adam Neumann as its charismatic pitchman, WeWork raised billions of dollars and grew rapidly, often doubling in revenue each year. At its peak, it was one of the country’s most valuable startups and operated offices around the world.

It also dabbled in somewhat tangential projects, like a private elementary school called WeGrow, two residential buildings called WeLive, and a gym concept called Rise By We.

WeWork may file its Chapter 11 petition in New Jersey, the Journal reported.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Temu Parent PDD Warns Current Profits Not Sustainable As Competition Heats Up In China
Temu Parent PDD Warns Current Profits Not Sustainable As Competition Heats Up In China
Aug 25, 2025
Temu parent PDD Holdings ( PDD ) stock is trading higher on Monday after the company reported fiscal second-quarter 2025 results. Revenue grew 7% year-on-year (Y/Y) to $14.52 billion (103.98 billion Chinese yuan), topping the analyst consensus estimate of $14.35 billion. During the earnings conference call, PDD executives highlighted steady growth in retail sales and expressed strong confidence in the long-term potential of China's consumer market. Also Read: PDD Margins Fall On...
BriaCell Therapeutics Awarded US$2 Million Grant to Advance Prostate Cancer Treatment
BriaCell Therapeutics Awarded US$2 Million Grant to Advance Prostate Cancer Treatment
Aug 25, 2025
09:40 AM EDT, 08/25/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) down 10% on last look, on Monday said it has been awarded a research grant of US$2 million by the National Cancer Institute (NCI) in the U.S., to advance Bria-PROS+, the company's newest personalized off-the-shelf immunotherapy for prostate cancer. The grant will fund the upcoming Phase 1/2a study...
Intel Secures $8.9 Billion Investment From US Government for 9.9% Equity Stake
Intel Secures $8.9 Billion Investment From US Government for 9.9% Equity Stake
Aug 25, 2025
09:03 AM EDT, 08/25/2025 (MT Newswires) -- Intel ( INTC ) shares rose early Monday following the company's announcement last week that the US government agreed to acquire a 9.9% stake in the chipmaker, as part of an $8.9 billion investment deal with the Trump administration. The US government will purchase 433.3 million shares of Intel ( INTC ) at...
BRIEF-Abbvie To Acquire Gilgamesh Pharmaceuticals' Bretisilocin
BRIEF-Abbvie To Acquire Gilgamesh Pharmaceuticals' Bretisilocin
Aug 25, 2025
Aug 25 (Reuters) - Abbvie Inc ( ABBV ): * ABBVIE TO ACQUIRE GILGAMESH PHARMACEUTICALS' BRETISILOCIN, A NOVEL, INVESTIGATIONAL THERAPY FOR MAJOR DEPRESSIVE DISORDER, EXPANDING PSYCHIATRY PIPELINE * ABBVIE INC ( ABBV ) - TO BUY BRETISILOCIN PROGRAM FOR UP TO $1.2 BILLION * ABBVIE ( ABBV ) - GILGAMESH WILL SPIN OFF A NEW ENTITY THAT WILL OPERATE UNDER...
Copyright 2023-2026 - www.financetom.com All Rights Reserved